Keywords
How to Cite
Abstract
Introduction. The use of the targeted drug ramucirumab, a vascular endothelial growth factor type 2 (VEGF2) inhibitor, in combination with chemotherapy (CT) paclitaxel/FOLFIRI is the standard of care for second-line treatment of patients with metastatic gastric cancer.
Case Description. A 72-year-old patient with disseminated gastric cancer (DGC) and a complex cardiac diagnosis received targeted therapy with ramucirumab in combination with chemotherapy with irinotecan and subsequent transition to paclitaxel (45 cycles in total) in the second and subsequent lines of treatment. In the absence of significant adverse events, the duration of response to targeted therapy with ramucirumab in combination with chemotherapy is 24 months. The mean life expectancy of an elderly patient with disseminated gastric cancer is 28 months.
Conclusion. The combination of ramucirumab with chemotherapy in the second and subsequent lines of treatment represents an effective therapeutic option with a favorable toxicity profile in elderly patients with gastric cancer who also have comorbidities.
References
Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23(5): 1011-27.-DOI: https://doi.org/10.1200/JCO.2005.06.081.
Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013; 273(2): 114-27.-DOI: https://doi.org/10.1111/joim.12019.
Schirizzi A., Arshadi A., Tolomeo D., et al. VEGFA status as a predictive marker of therapy outcome in metastatic gastric cancer patients following ramucirumab-based treatment. Biomedicines. 2023; 11(10): 2721.-DOI: https://doi.org/10.3390/biomedicines11102721.
Khan U., Shah M.A. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. Expert Opin Biol Ther. 2019; 19(11): 1135-1141.-DOI: https://doi.org/10.1080/14712598.2019.1656715.
Sorokin M., Poddubskaya E., Baranova M., et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020; 6(2): a004945.-DOI: https://doi.org/10.1101/mcs.a004945.
Yang M.J., Choi Y.J., Kim H.J., et al. Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report. Medicine (Baltimore). 2021; 100(7): e24795.-DOI: https://doi.org/10.1097/MD.0000000000024795.
Jun C., Yamauchi S., Yube Y., et al. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer. Surg Case Rep. 2023; 9(1): 86.-DOI: https://doi.org/10.1186/s40792-023-01668-x.
Hironaka S. Anti-angiogenic therapies for gastric cancer. Asia Pac J Clin Oncol. 2019; 15(4): 208-217.-DOI: https://doi.org/10.1111/ajco.13174.
Fuchs C.S., Tomasek J., Yong C.J., et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911): 31-39.-DOI: https://doi.org/10.1016/S0140-6736(13)61719-5.
Wilke H., Muro K., Van Cutsem E., et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11): 1224-35.-DOI: https://doi.org/10.1016/S1470-2045(14)70420-6.
Mehta R., Kommalapati A., Kim R.D. The Impact of ramucirumab treatment on survival and quality of life in patients with gastric cancer. Cancer Manag Res. 2020; 12: 51-57.-DOI: https://doi.org/10.2147/CMAR.S199827.
Fuchs C.S., Tabernero J., Tomášek J., et al. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016; 115(8): 974-982.-DOI: https://doi.org/10.1038/bjc.2016.293.
Tabernero J., Hozak R.R., Yoshino T., et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol. 2018; 29(3): 602-609.-DOI: https://doi.org/10.1093/annonc/mdx767.
Refolo M.G., Lotesoriere C., Lolli I.R., et al. Molecular mechanisms of synergistic action of ramucirumab and paclitaxel in gastric cancers cell lines. Sci Rep. 2020; 10(1): 7162.-DOI: https://doi.org/10.1038/s41598-020-64195-x.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024